Despite the initial successes of gene delivery applications, they faced on several intrinsic drawbacks including toxicity and immunogenicity. Therefore, alternative gene‐delivery systems derived from recombinant peptides have emerged and is rapidly developing. Human epidermal growth factor receptor‐3 (HER3) shows high activity in tumor resistance to anti‐human epidermal growth factor receptor 2 (HER2) therapies. In this study, an affibody molecule against HER3 is conjugated to a biomimetic peptide RALA (an amphipathic and cationic peptide enriched with arginine) and the ability of the fusion vector for targeting HER3 and afterward delivering specific genes in breast cancer cells is evaluated. The results demonstrate that the biopolymeric platform, which contains an affibody‐conjugated RALA peptide, can effectively condense DNA into nanoparticles and target the overexpressed HER3 receptors in breast cancer cells and transfer specific genes. The use of such a recombinant biopolymer may pave the way for the development of sensitive and effective diagnostic and treatment tool for breast cancer.

中文翻译：

---

ZHER3-Affibody靶向纳米载体的基因传递到HER3过表达的乳腺癌细胞的发展。

尽管基因递送应用取得了最初的成功，但它们仍面临一些固有的缺点，包括毒性和免疫原性。因此，衍生自重组肽的替代基因递送系统已经出现并且正在迅速发展。人表皮生长因子受体3（HER3）对抗人表皮生长因子受体2（HER2）疗法具有很高的抗肿瘤活性。在这项研究中，将针对HER3的亲和分子与仿生肽RALA（富含精氨酸的两亲和阳离子肽）缀合，并评估了融合载体靶向HER3并随后在乳腺癌细胞中传递特定基因的能力。结果表明，该生物聚合物平台包含亲和体偶联的RALA肽，可以有效地将DNA浓缩成纳米颗粒，并靶向乳腺癌细胞中过度表达的HER3受体并转移特定基因。这种重组生物聚合物的使用可以为开发灵敏有效的乳腺癌诊断和治疗工具铺平道路。